Skip to main content

Table 1 Clinical and infection characteristics of patients treated with IFNγ for cohort 1 and Cohort 2. AB/C = antibodies per cell. MFI = Mean Fluorescence Intensity

From: Multicentric experience with interferon gamma therapy in sepsis induced immunosuppression. A case series

Cohort 1
  Age Diagnosis at admission Day of ICU Secondary infection microorganism Antibiotic treatment mHLA-DR (AB/C) Injections of IFNγ Day-15 outcome
1 30 Cardiac arrest 10 VAP Pseudomonas aeruginosa amikacin (4 days) + colimycin (2 days) + cefepim (2 days) 2419 5 alive
2 83 Postop cardiogenic shock 29 VAP Pseudomonas aeruginosa, Stenotrophomonas maltophilia ciprofloxacin (11 days) + ceftazidime (13 days) 4092 6 alive
3 73 Cardiogenic shock 16 VAP Stenotrophomonas maltophilia, Pseudomonas aeruginosa piperacillin + tazobactam (4 days) 1492 4 alive
4 63 Peritonitis 16 VAP Pseudomonas aeruginosa Imipenem (7 days) 1427 3 dead
5 42 Peritonitis 10 VAP, peritonitis Pseudomonas aeruginosa, Aspergillus fumigatus piperacillin+ tazobactam (10 days) 1547 6 alive
6 64 Peritonitis 37 Peritonitis
VAP
Stenotrophomonas maltophilia + Enterobacter Cloacae + Enterococcus feacalis
Enterobacter cloacae + Stenotrophomonas maltophilia
tigecycline + colimycin 2666 3 alive
7 65 Postoparative pneumonia 134 VAP Streptococcus agalactiae none 3289 5 alive
8 56 Pneumonia 11 VAP Stenotrophomonas maltophilia
EBV reactivation
piperacillin + tazobactam (10 days) 4991 4 alive
9 34 Pneumonia 15 VAP Pseudomonas aeruginosa
Aspergillus fumigatus
colimycine (15 days) amikacine (aerosolized) 15 days Voriconazole started 5428 5 alive
10 56 Cervical cellulitis septicemia 13 Perirenal abscess Staphylococcus aureus oxacilline + Pefloxacine (12 days) 2056 7 alive
11 60 Fasciitis 38 Fasciitis Pseudomonas aeruginosa Imipenem + amikacine (3 days) 5132 5 alive
12 74 Keto-acidosis 40 VAP, lung abcess, pleuresis Pseudomonas aeruginosa, Citrobacter freundii Imipenem (7 days) 7073 4 Alive
13 82 Rectal Fistulae & fasciitis 9 Tight muscle infection Gram negative multiple bacteriaanaerobes Piperacillin + tazobactam (4 days)
Imipenem + amikacine (7 days)
2168 3 Alive
Cohort 2
Age Diagnosis at admission Infection focus Delay between admission and IFNγ Microorganism Antibiotic treatment SOFA-score at admission mHLA-DR Expression (MFI) Outcome
74 Septic Shock Abdominal 4 Unknown Ceftriaxon 12 16.0 Death
73 Abdominal 3 Klebsiella pneumoniae Ceftriaxon 8 14.6 Alive
74 Bilary 1 Multi-resistant E coli, Clostridium perfringens Piperacillin / tazobactam, ceftriaxon erytromycin 14 5.6 Alive
80 Abdominal 5 Staphylococcus haemolyticus, Candida albicans Vancomycin and Piperacillin / tazobactam, myfungin / fluconazole 9 73.6 Death
  1. VAP Ventilator-associated pneumonia, EBV Ebstein Barr virus, CMV cytomegalovirus